KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer
KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024
Charles River Laboratories Reduces Workforce by 3% Amid Q2 Revenue Decline
Charles River Laboratories, workforce reduction, layoffs, Q2 revenue drop, biopharma industry, restructuring initiatives
Revolutionizing Drug Discovery: AI-Driven Solutions for Efficient and Personalized Treatments
Artificial Intelligence (AI) in Drug Discovery, Machine Learning (ML) for Drug Development, Quantum Computing in Pharmaceutical Research, Personalized Medicine, Efficient Drug Discovery Processes, AI-Driven Target Identification and Validation, Quantum Machine Learning (QML) for Drug Discovery
FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy
Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology
WHO Prequalifies Bavarian Nordic’s MVA-BN Vaccine as First Mpox Vaccine
WHO, mpox vaccine, Bavarian Nordic, MVA-BN, prequalification, global health, vaccine access
Atea Pharmaceuticals’ Bemnifosbuvir Fails to Meet Primary Endpoint in Phase 3 COVID-19 Treatment Trial
Atea Pharmaceuticals, Bemnifosbuvir, COVID-19 treatment, Phase 3 trial, Polymerase inhibitor, SUNRISE-3 trial
FDA Approves TREMFYA (Guselkumab) for Moderately to Severely Active Ulcerative Colitis
TREMFYA, Guselkumab, FDA Approval, Ulcerative Colitis, Inflammatory Bowel Disease, Johnson & Johnson
FDA Issues Warning on Rare Liver Injury Risk with Veozah (Fezolinetant) for Menopausal Hot Flashes
Veozah (fezolinetant), FDA warning, Liver injury, Menopausal hot flashes, Nonhormonal prescription medicine, Neurokinin 3 (NK3) receptor antagonists
Biopharma Layoff Tracker 2024: Ongoing Industry Downsizing
Biopharma layoffs, 2024 layoffs, pharmaceutical industry downsizing, biotech job cuts, pharma restructuring
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial